Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) Director Ra Capital Management, L.P. acquired 1,000 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were bought at an average price of $32.43 per share, for a total transaction of $32,430.00. Following the transaction, the director owned 5,967,439 shares of the company’s stock, valued at $193,524,046.77. This trade represents a 0.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Spyglass Pharma Stock Performance
Shares of SGP stock traded down $1.75 on Wednesday, reaching $29.68. The stock had a trading volume of 95,000 shares, compared to its average volume of 109,105. The stock has a market cap of $993.09 million and a P/E ratio of -3.84. Spyglass Pharma, Inc. has a 1 year low of $17.06 and a 1 year high of $39.92. The company has a 50 day simple moving average of $28.90 and a 200 day simple moving average of $24.90.
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.07). On average, equities research analysts anticipate that Spyglass Pharma, Inc. will post -2.77 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Spyglass Pharma
A number of institutional investors and hedge funds have recently bought and sold shares of SGP. Bank of New York Mellon Corp purchased a new position in shares of Spyglass Pharma in the second quarter valued at about $533,000. Bank of America Corp DE purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $726,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $308,000. First Light Asset Management LLC purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $9,716,000. Finally, Affinity Asset Advisors LLC bought a new stake in Spyglass Pharma during the 1st quarter valued at approximately $6,478,000.
Analyst Ratings Changes
SGP has been the subject of several recent research reports. UBS Group reissued a “buy” rating on shares of Spyglass Pharma in a report on Monday, October 5th. Weiss Ratings raised shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a report on Friday. Stifel Nicolaus raised their target price on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, November 13th. Wall Street Zen raised shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Finally, HC Wainwright upped their price target on shares of Spyglass Pharma from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Spyglass Pharma has an average rating of “Moderate Buy” and an average target price of $45.83.
View Our Latest Report on Spyglass Pharma
Spyglass Pharma Company Profile
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
See Also
- Five stocks we like better than Spyglass Pharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
